Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3009365018 | Sodium glucose cotransporter subtype 2 inhibitor | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3520826018 | Substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action (substance) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3559322015 | Substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Sodium glucose cotransporter subtype 2 inhibitor | Is a | Antidiabetic agent | false | Inferred relationship | Some | ||
| Sodium glucose cotransporter subtype 2 inhibitor | Is a | Enzyme inhibitor | false | Inferred relationship | Some | ||
| Sodium glucose cotransporter subtype 2 inhibitor | Is a | Drug or medicament (substance) | true | Inferred relationship | Some | ||
| Sodium glucose cotransporter subtype 2 inhibitor | Has disposition (attribute) | Sodium glucose cotransporter subtype 2 inhibitor (disposition) | true | Inferred relationship | Some | ||
| Sodium glucose cotransporter subtype 2 inhibitor | Is a | Substance categorized by disposition | false | Inferred relationship | Some | ||
| Sodium glucose cotransporter subtype 2 inhibitor | Is a | Substance with cellular transport inhibitor mechanism of action (substance) | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Dapagliflozin (substance) | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Canagliflozin | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Empagliflozin | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Product containing sodium glucose cotransporter subtype 2 inhibitor (product) | Has active ingredient | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | 1 |
| Ertugliflozin | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Dapagliflozin propanediol | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Canagliflozin hemihydrate (substance) | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Dapagliflozin propanediol monohydrate (substance) | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Ertugliflozin pidolate | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Remogliflozin etabonate | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Canagliflozin anhydrous | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some | |
| Dapagliflozin propanediol anhydrous | Is a | True | Sodium glucose cotransporter subtype 2 inhibitor | Inferred relationship | Some |
Reference Sets
Belgian subset for AllergyIntolerance, causative agent, drug
FHIR